FR 236924 is a PKCε activator, which may be useful as therapeutic agents for the treatment of Alzheimer disease as lowered PKCε activator levels are assocaited with Aβ degradation (a hallmark of Alzheimer’s disease).
fr 236924 is a selective activator of pkc-ε [1].pkc is a monomeric ca2+- and phospholipid-dependent ser/thr protein kinase and plays an important role in growth factor-activated signaling and malignant transformation.fr 236924 (dcp-la) is a selective pkc-ε activator. in pc-12 cells, dcp-la (10 nm-100 μm) activated pkc in a concentration dependent way with the maximal effect at 100 nm. in the cell-free system, dcp-la (100 μm) significantly activated pkc-ε and exhibited >7-fold potency over other pkc isozymes (α,βi, βii, γ, δ, μ, η and ζ), suggesting that dcp-la was a selective pkc-ε activator. dcp-la exhibited the maximal effect on pkc-ε at 100 μm. the activation of pkc-ε induced by dcp-la (100 μm) was inhibited by dioleoyl-phosphatidylserine in a concentration dependent way, suggesting that dcp-la might bound to the phosphatidylserine binding site on pkc-ε. however, dioleoyl-phosphatidylserine increased dcp-la (100 μm)-induced pkc-ε activation in a concentration dependent way, suggesting a different activation mechanism [1]. in xenopus oocytes expressing α7 receptors, fr236924 (10 μm) induced a persistent increased α7 receptor responses to 144% via a pkc pathway. in rat hippocampal slices, fr236924 (10 nm to 10 μm) facilitated hippocampal neurotransmission [2].in the hippocampus of rats, fr236924 induced glutamate release and facilitated hippocampal synaptic transmission through pkc [3].
DCP-LA is a selective PKC-epsilon (PKC-ε) activator. In the in situ PKC assay with a reversed phase high-performance liquid chromatography, DCP-LA significantly activated PKC in PC-12 cells in a concentration (10 nM-100 μM)-dependent manner, with the maximal effect at 100 nM. DCP-LA has over a 7-fold greater potency for activation of PKC-ε over other PKC isozymes.
DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model[3].
| Animal Model: | Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)[3] |
| Dosage: | 1 mg/kg |
| Administration: | Oral gavage; once daily for 7 days; sacrificed mice on days 28 |
| Result: | Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%. |
[1]. kanno t, yamamoto h, yaguchi t, et al. the linoleic acid derivative dcp-la selectively activates pkc-epsilon, possibly binding to the phosphatidylserine binding site. j lipid res, 2006, 47(6): 1146-1156.
[2]. tanaka a, nishizaki t. the newly synthesized linoleic acid derivative fr236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. bioorg med chem lett, 2003, 13(6): 1037-1040.
[3]. yamamoto s, kanno t, nagata t, et al. the linoleic acid derivative fr236924 facilitates hippocampal synaptic transmission by enhancing activity of presynaptic alpha7 acetylcholine receptors on the glutamatergic terminals. neuroscience, 2005, 130(1): 207-213.
